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CONCLUSION: Superior clinical efficacy combined with
substantial cost savings for at least one year of follow up
conferred to enoxaparin a place of choice in acute cardi-
ology therapy.
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OBJECTIVE: To determine the cost-effectiveness of
thrombosis prevention with Clopidogrel versus Ticlopi-
dine in Russia, taking into account side effect such as
agranulocytosis (neutropenia) using a decision analysis.
METHODS: Pharmacoeconomic comparison using a de-
cision-tree model was based on the assumption that
Ticlopidine (250 mg daily) causes short-duration neutro-
penia in 0,8% of patients compared to 0,04% of patients
on Clopidogrel (37,5 mg daily) one month after treat-
ment starts. The probabilities of neutropenia were de-
rived from multi-center clinical trials of antithrombotic
therapy safety. Calculated costs included cost of study
drugs and direct medical costs for neutropenia treatment.
A neutropenia treatment scheme was analyzed by review-
ing medical charts of patients with short-duration neutro-
penia at the Federal Hematological Center. Effectiveness
was measured by percentage reduction in spontaneous
platelet aggregation (SPA) in a comparative clinical study
including 70 patients with thrombophilia. Cost effective-
ness ratio (CER) was defined for both drugs and incre-
mental cost-effectiveness ratio (ICER) was determined.
RESULTS: The mean costs of medication treatment were
1221 rubles (42,1$) for Clopidogrel and 795 rubles
(27,4$) for Ticlopidine. The median direct medical cost
for treatment of neutropenia was 28,126 rubles (969,9$)
per patient. Expected costs for antiplatelet therapy, tak-
ing into account the probability of neutropenia, was
1020 rubles (35,2$) for Ticlopidine and 1232 rubles
(42,5$) for Clopidogrel. The CER for Clopidogrel was
19,4 rubles (0,67$) and 20,6 rub (0,71$) for Ticlopidine
per 1% of SPA reduction. The ICER for Clopidogrel vs.
Ticlopidine was 14,5 rub (0,5$) per 1% SPA reduction.
CONCLUSION: Clopidogrel is more effective and safe
than Ticlopidine. Though costs for Clopidogrel including
treatment of side effects (neutropenia) were higher than
for Ticlopidine, ICER shows that additional effects can
be achieved at a reasonable cost.
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OBJECTIVE: To conduct an economic analysis of the
PURSUIT trial in the UK for patients with unstable an-
gina or non-Q-wave myocardial infarction (MI) admitted
to hospital and randomized to eptifibatide (GPIIb/IIIa) or
placebo in addition to usual therapy.
METHODS: Health-care resource consumption was col-
lected prospectively for all patients in the PURSUIT trial.
Unit costs were developed for the UK and applied to the
resources consumed in the trial to estimate the cost per
patient treated during index hospital stay and at six
months follow-up. Analyses were conducted using resource
consumption from the UK sub population, Western Eu-
ropean (WE) sub population, and the total PURSUIT trial
population. Long term outcome measures were based on
life expectancy estimated from six-month PURSUIT data of
the WE sub-population and the North American (NA) 
WE sub populations.
RESULTS: Initial hospital and six-month costs for eptifi-
batide patients including drug cost were slightly higher
than the placebo group using the WE and overall trial
population resources. UK-specific resource consumption
was lower in the eptifibatide group. The difference in 30-
day rate of death and MI was 1% (NS) for WE and 1.5%
(p  0.04) for the overall trial. At six months, MI rates
were further decreased for eptifibatide but no difference
existed in mortality between the groups. The CE ratios
(discounted at 3%) using WE or overall resources are
£8,436 and £12,591 respectively using WE survival or
£3,418 and £5,036 using WE  NA survival. Using UK
resources, eptifibatide is cost saving in either survival sce-
nario.
CONCLUSION: The cost-effectiveness ratios for eptifi-
batide in the UK all fall within an acceptable range for
adopting new technology. The impact of resource con-
sumption data on the cost-effectiveness ratio underscores
the importance of the source of treatment-pattern data
and the need for prospective or retrospective data collec-
tion to reflect country-management styles.
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OBJECTIVE: The objective of this analysis was to evalu-
ate the health-economic benefits of using amlodipine in
patients undergoing angioplasty procedures from the per-
spectives of the Canadian Ontario Ministry of Health
and the Norwegian National Health Service.
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METHODS: A decision-tree model was constructed to
determine the total expected cost per patient for a four-
month time period following an initial angioplasty. The
model used clinical data from the Coronary Angioplasty
Amlodipine Restenosis Study (CAPARES), a four-month,
multicenter, double-blind, placebo-controlled trial con-
ducted to investigate the effect of amlodipine on resteno-
sis and clinical events in patients undergoing PTCA. Clin-
ical endpoints of interest included MI, repeat PTCA,
CABG, and all-cause mortality. Clinical experts from
Canada and Norway were enlisted and a modified Delphi
study approach was used to estimate the amount of
health-care resources consumed for each clinical out-
come.
RESULTS: The adjunctive use of amlodipine improved
the four-month success rate of angioplasties by 9.4%
(83.7% vs 93.1%). In other words, there was a decrease
in the number of adverse clinical endpoints after an an-
gioplasty. There was an absolute reduction of 2.0%,
4.7%, and 2.7% in the rate of MI, PTCA, and CABG, re-
spectively. The total expected cost per patient using am-
lodipine was $6,398 (US$4,328) in Canada and kr35,652
(US$4,004) in Norway. The total expected cost per pa-
tient not using amlodipine was $6,519 (US$4,410) in
Canada and kr37,150 (US$4,172) in Norway. The model
demonstrated the magnitude of the potential savings re-
sulting from the improved clinical outcomes for patients
using amlodipine with PTCA. Overall, fewer health re-
sources were utilized by amlodipine patients, resulting in
savings in total expected cost of treatment of $121
(US$82) in Canada and kr1, 498(US$168) in Norway.
CONCLUSIONS: The adjunctive use of amlodipine is a
cost-effective therapeutic strategy to achieve more favor-
able clinical outcomes in patients undergoing PTCAs in
Canada and Norway.
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Levosimendan is a novel intravenous drug that increases
the calcium sensitivity of cardiac myofilaments, improves
haemodynamic function and symptoms, and decreases rel-
ative mortality of patients with low-output heart failure.
OBJECTIVE: To estimate the cost-effectiveness of treat-
ment with levosimendan compared to dobutamine in pa-
tients with severe low-output heart failure.
METHODS: The economic evaluation was based on a
European cinical trial (LIDO), in which 203 patients with
severe heart failure were randomised to 24h infusion
with either levosimendan or dobutamine. Survival and re-
source utilisation data were collected for six months, and
survival was extrapolated up to three years based on data
from the CONSENSUS trial. Costs were based on drug
usage and hospitalisation in the LIDO trial and the six-
month follow-up. The price of levosimendan was arbi-
trarily set at €668 (USD 600) per 5 ml vial, whereas the
mean actual cost of dobutamine in the eight countries
participating in the study was calculated (€13.70 per
vial). The mean cost of a hospital day in the eight coun-
tries was used (basis 1998).
RESULTS: The mean survival over six months was 157
(SD 51.5) days in the levosimendan group and 139 (SD
64.0) days in the dobutamine group (p  .01). When ex-
trapolated up to three years, the gain in life expectancy
was estimated at 0.35 years (discounted by 3%). Levosi-
mendan increased the average cost per patient by
€1,154. The incremental cost per life year saved (LYS)
was €3,340. When accounting for a cost in added years
of life, the incremental cost per LYS was higher, as ex-
pected. For example in Sweden, the cost per LYS in-
creased from €3,000 to €20,800.
CONCLUSIONS: The cost per LYS using levosimendan,
both with and without accounting for costs in added
years of life, compares favourably with other cost-effec-
tiveness analyses in cardiology, e.g. USD 33,000/LYS for
TPA treatment in the GUSTO trial.
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OBJECTIVE: Bradycardia is a common condition char-
acterized by a heart rate of less than 60 beats per minute.
Among patients with bradycardia, atrial tachyarrhyth-
mias may also be present at the time of pacemaker im-
plant, or may subsequently develop during the lifetime of
the device. We conducted a study in the US, Germany
and the UK to assess the additional burden of health-care
utilization and associated costs imposed by atrial tachy-
arrhythmia among bradycardia patients.
METHODS: In the US, electronic claims including hospi-
tal inpatient admissions, emergency room admissions,
outpatient physician visits, outpatient tests and proce-
dures, and pharmacy claims data were obtained from a
large-group model managed-care organization with broad
geographic representation. In Europe, resource utilization
data were collected via a survey of cardiologists (n  5 in
Germany, n  4 in UK). For the survey, two patient
groups were defined: patients with bradycardia and no
coexisting atrial tachyarrhythmias, and those with co-ex-
isting diagnoses of bradycardia and atrial tachyarrhyth-
